Results 191 to 200 of about 7,789 (204)

Upadacitinib Is Effective and Safe in Both Ulcerative Colitis and Crohn’s Disease: Prospective Real-World Experience

Clinical Gastroenterology and Hepatology, 2023
David T Rubin
exaly  

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis

New England Journal of Medicine, 2021
David T Felson, Josef S Smolen
exaly  

Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies

Journal of Allergy and Clinical Immunology, 2023
E Guttman-Yassky
exaly  

Upadacitinib for the treatment of active non-radiographic axial spondyloarthritis (SELECT-AXIS 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet, The, 2022
exaly  

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results

Journal of Allergy and Clinical Immunology, 2022
Jonathan I Silverberg, Marjolein de Bruin-Weller, Thomas Bieber   +2 more
exaly  

Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2

Annals of the Rheumatic Diseases, 2021
Philip J Mease, Jaclyn K Anderson, Filip E Van Den Bosch   +2 more
exaly  

Upadacitinib

Reactions Weekly, 2022
openaire   +2 more sources

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study

Lancet, The, 2019
Josef S Smolen, Paul Emery, William F C Rigby   +2 more
exaly  

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial

Lancet, The, 2018
Mark C Genovese, Roy M Fleischmann, Bernard Combe   +2 more
exaly  

Upadacitinib for ulcerative colitis

Lancet, The, 2022
exaly